Please use this identifier to cite or link to this item: https://dspace.iiti.ac.in/handle/123456789/10897
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaig, Mirza Saqib;Rajpoot, Sajjan;Mahajan, PratikSolanki, Kundan;Saqib, Uzma;en_US
dc.date.accessioned2022-11-03T19:47:36Z-
dc.date.available2022-11-03T19:47:36Z-
dc.date.issued2022-
dc.identifier.citationBaig, M. S., Rajpoot, S., Ohishi, T., Savai, R., Seidel, S., Kamennaya, N. A., . . . Saqib, U. (2022). Anti-lung cancer properties of cyanobacterial bioactive compounds. Archives of Microbiology, 204(10) doi:10.1007/s00203-022-03194-0en_US
dc.identifier.issn0302-8933-
dc.identifier.otherEID(2-s2.0-85137160286)-
dc.identifier.urihttps://doi.org/10.1007/s00203-022-03194-0-
dc.identifier.urihttps://dspace.iiti.ac.in/handle/123456789/10897-
dc.description.abstractLung cancer, the most prevalent gender-independent tumor entity in both men and women, is among the leading cause of cancer-related deaths worldwide. Despite decades of effort in developing improved therapeutic strategies including immunotherapies and novel chemotherapeutic agents, only modest improvements in outcome and long-term survival of lung cancer patients have been achieved. Therefore, exploring new and exceptional sources for bioactive compounds that might serve as anti-cancer agents might be the key to improving lung cancer therapy. On account of diverse forms, cyanobacteria might serve as a potential source for compounds with potential therapeutic applicability against malignant disorders, including cancer. The assorted arrays of metabolic mechanisms synthesize a plethora of bioactive compounds with immense biological potential. These compounds have been proven to be effective against various cancer cell lines and xenograft animal models. The present review provides an overview of the most promising cyanobacteria-derived bioactive compounds proven to exhibit anti-cancer properties in in-vitro and in-vivo studies and highlights their applicability as potential therapeutic agents with a focus on their anti-lung cancer properties. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.en_US
dc.language.isoenen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.sourceArchives of Microbiologyen_US
dc.subjectantillatoxin b; antineoplastic agent; apratoxin d; apratoxin f; apratoxin g; apratoxin h; aurilide b; aurilide c; calothrixin a; calothrixin b; coibamide a; curacin A; dolastatin 10; dolastatin 15; ethyl tumonoate a; hoiamide a; hoiamide b; isomalyngamide a; jamaicamide a; jamaicamide b; jamaicamide c; kalkipyrone b; kalkitoxin; lagunamide c; largazole; lyngbyabellin a; lyngbyabellin b; lyngbyabellin c; lyngbyabellin d; majusculamide C; malevamide d; malyngamide 2; malyngamide c; malyngamide j; malyngamide k; palauamide; palmyramide a; phycocyanin; polysaccharide; symplocamide; unclassified drug; veraguamide a; wewakazole; wewakpeptin a; wewakpeptin b; antineoplastic agent; antineoplastic activity; cyanobacterium; human; in vitro study; in vivo study; lung cancer; nonhuman; pharmacokinetic parameters; Review; animal; female; metabolism; neoplasm; Animals; Antineoplastic Agents; Cyanobacteria; Female; Humans; Neoplasmsen_US
dc.titleAnti-lung cancer properties of cyanobacterial bioactive compoundsen_US
dc.typeReviewen_US
Appears in Collections:Department of Biosciences and Biomedical Engineering

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetric Badge: